Navigation Links
Cipla Offers Modest AIDS Drug Price Cut: 'Not Nearly Enough,' says AHF
Date:12/13/2007

le now estimated to be living with HIV/AIDS in India, only around 85,000 are receiving lifesaving antiretroviral treatment," said Dr. Mahesh Ganesan, Advocacy Coordinator for AIDS Healthcare Foundation. "If the average income is 29000 rupees -- which, according to the World Bank, is India's gross national income -- then whether a year's supply of medicines costs 54000 rupees a year or 46800 makes little difference, as it is still far too high and still beyond the reach of most Indians in need."

This past August, AHF and several Indian civil society partners and co- sponsors rolled out the drug pricing advocacy campaign with a print ad headlined, "Profit at What Cost? AIDS Drugs for All." The ad, which appeared in prominent Indian newspapers questioned Cipla regarding a price difference of 150% between what Cipla has offered African and Indian purchasers for the lifesaving antiretroviral combination Viraday. Cipla has yet to dispute the fact that it offers dramatically different prices to Africa than to its own fellow countrymen for this drug.

Because of questions raised by the drug-pricing advocacy campaign, Cipla is currently under investigation by the Monopolies and Restrictive Trade Practices Commission (MRTPC), India's anti-trust commission that probes monopolistic, restrictive and unfair trade practices, over its possible overpricing of Viraday.

AIDS Healthcare Foundation (AHF) operates free AIDS treatment clinics in India under AHF India Cares in Mysore, New Delhi and in Guwahati, Assam in collaboration with the National AIDS Control Organization (NACO). Additionally, in the Asia/Pacific region, AHF currently provides free antiretroviral treatment to people in need through its clinics in Thailand, Viet Nam, Cambodia and China.

AIDS Healthcare Foundation is the US' largest non-profit HIV/AIDS healthcare, research, prevention and education provider. AHF currently provides medical care and/or services to more than 61,000 individuals in
'/>"/>

SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
2. Health care incentive model offers collaborative approach
3. Eye-staining technique offers early detection for dry eye syndrome
4. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
7. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
8. Regence Offers InterM to Fill Gap for the Uninsured
9. Super Jake Foundation Offers Hope for Pediatric Cancer
10. Concentra Offers a Cure For What Ails You
11. National Non-Profit Organization Offers Free Mental Health Services to Military and Military Families
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...RNewswire/ -- BAPTIST HEALTH, a six-hospital,syst...gest health system, has,expanded its use of Clini...,solution that enabled the system,s pharmacists to...ve more than $1 million. , "Data we collect...hat,CareFocus prompts approximately half of the p...
(Date:12/4/2008)...se seen with standard dose of daunorubicin, study ...ws) -- A high dose of the chemotherapy drug daunor...usly untreated acute myeloid leukemia (AML), preli...tional Cancer Institute (NCI) show. , AML is a ...cluded 633 patients, aged 16 to 60, who were rando...
(Date:12/4/2008)...s Leaders of Virginia, Maryland and D.C. AIDS Offi...wswire/ -- Nationally, Washington, D.C. ranks firs...C., 82 percent are African American. In an effort...the South, today,s Living Quilt roundtable at the ...e leaders of the Virginia, Maryland and District o...
(Date:12/4/2008)...his December, and on the eve of its 35th Anniversa...unch an integrated Season of Giving marketing camp... long way. The initiative, designed to drive perso...harity and its three core programs: Ronald McDonal...d McDonald Care Mobile. , ...
Breaking Medicine News(10 mins):Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 3Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 3
...gs from a recent study researchers say, the ancien...cal application. Lymphoma patients// who took part...n those in a control group. The study was conducte...ther undergoing treatment or who had concluded tre...
...extended exposure to sunlight may lead to age-rela...egeneration an eye // disorder that can cause blin...ts for five years and more than 2,700 patients for...86 years old. Participants who reported being in t...
...s( DVT ) is a blood clot that develops deep in the...lung. // People who require prolonged bed rest ar... blood circulation ,especially patients in intensi...a serious risk for DVT. Recent studies have shown ...
...w individuals in lower socioeconomic groups, as me...ul days than those with // higher socioeconomic st...rger impact on their health. While those with more...y are not as affected by it. For the study, more t...
Other Medicine News:
(Date:12/2/2008)...wire-FirstCall/ -- Biopure Corporation,(Nasdaq: ...l Research Center,(NMRC) has submitted to the Foo...gational new drug (IND) application to conduct a c... Hemopure(R) [hemoglobin glutamer - 250 (bovine)],...uma patients. The study is,entitled "Operation Re...
(Date:12/2/2008).../ -- Horizon Therapeutics, Inc., a,privately held...wo pivotal,Phase 3 trials evaluating its lead inv...primary endpoints. HZT-501, a novel, proprietary f...n and famotidine, demonstrated a,statistically si...dal,anti-inflammatory drug (NSAID)-induced upper ...
(Date:12/1/2008)...2 A study has found tha...ique for imaging the breast, is not affected by ei...two factors that limit the effectiveness of standa...s will be presented today at the annual meeting of... , , "The ability of PEM to detect cancer ...
(Date:12/1/2008)...- S*BIO Pte Ltd today announced the initiation of ... orally-active JAK2 inhibitor, in leading medical ...opathic myelofibrosis (CIMF). , , The tria...ity of SB1518 in patients with CIMF and is expecte... the study will assess the safety profile and eval...
Breaking Medicine Technology:U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Minorities More Likely to Die in ER 27526 1Minorities More Likely to Die in ER 27526 2Minorities More Likely to Die in ER 27526 3Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 1Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 1Douglas Oberhelman Elected to Lilly Board of Directors 8390 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 3Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 1Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 2
...DGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - Combin... preliminary results of,a phase 2 clinical trial s...prednisolone and the antidepressant paroxetine),an...oid arthritis,(RA). This trial served two importan...t of 3mg of prednisolone alone (a very low dose),i...
...Y, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek,P...sentation of,positive Phase 2 clinical data demons...ntial for INO-1001 as a preventative agent for,car...n subjects,with acute ST-elevated myocardial infar...nary intervention. The presentation was,made in a ...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
Medicine Products: